Loading…
Vascular endothelial growth factors and angiopoietins in presentations and prognosis of papillary thyroid carcinoma
Aims Angiogenesis from thyroid cancer cell plays the important roles in post‐surgical persistent, recurrent, and metastatic papillary thyroid cancer (PTC). This study is to investigate the expression of angiopoietin‐1 (Ang‐1), angiopoietin‐2 (Ang‐2), Tek/Tie‐2 receptor, and vascular endothelial grow...
Saved in:
Published in: | Journal of surgical oncology 2011-04, Vol.103 (5), p.395-399 |
---|---|
Main Authors: | , , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Summary: | Aims
Angiogenesis from thyroid cancer cell plays the important roles in post‐surgical persistent, recurrent, and metastatic papillary thyroid cancer (PTC). This study is to investigate the expression of angiopoietin‐1 (Ang‐1), angiopoietin‐2 (Ang‐2), Tek/Tie‐2 receptor, and vascular endothelial growth factors (VEGF) in normal, benign thyroid tissues and different stage of PTC. We expect angiogenetic factors are important in the presentation of local‐regional neck or distant metastases in PTC.
Materials and Results
A total of 101 tissues from the subjects underwent thyroidectomy were enrolled in the study. There were 22 control and 79 thyroid cancer patients in different TNM stagings were collected. Ang‐1 illustrated highest mean immunostaining score in metastatic group. Comparing with normal and benign thyroid tissues, thyroid cancer tissues illustrated significantly high expression of three angiogenetic factors and Tie‐2 receptor. Of the PTC, significantly high expression of three angiogenetic factors and Tie‐2 receptor were illustrated in recurrent cases. VEGF showed statistical difference in disease‐free cancer mortality, and recurrent groups.
Conclusions
Immunochemical staining illustrated VEGF, Ang‐1, Ang‐2 expression in PTC tissues related to clinical staging; however, we need more information concerning these factors with long‐term follow‐up results. J. Surg. Oncol. 2011; 103:395–399. © 2010 Wiley‐Liss, Inc. |
---|---|
ISSN: | 0022-4790 1096-9098 |
DOI: | 10.1002/jso.21844 |